BlackRock Inc (BLK)vsBristol-Myers Squibb Company (BMY)
BLK
BlackRock Inc
$1,084.83
+1.60%
FINANCIAL SERVICES · Cap: $165.75B
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 89% more annual revenue ($48.48B vs $25.64B). BLK leads profitability with a 24.4% profit margin vs 15.0%. BLK appears more attractively valued with a PEG of 1.33. BLK earns a higher WallStSmart Score of 78/100 (B+).
BLK
Strong Buy78
out of 100
Grade: B+
BMY
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLK.
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.6%
Large-cap with strong market position
Keeps 24 of every $100 in revenue as profit
Revenue surging 27.0% year-over-year
Earnings expanding 45.9% YoY
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Weak financial health signals
Negative free cash flow — burning cash
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BLK
The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 35.6%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bear Case : BLK
The primary concerns for BLK are P/E Ratio, Piotroski F-Score, Free Cash Flow.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Key Dynamics to Monitor
BLK profiles as a growth stock while BMY is a value play — different risk/reward profiles.
BLK carries more volatility with a beta of 1.46 — expect wider price swings.
BLK is growing revenue faster at 27.0% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Bottom Line
BLK scores higher overall (78/100 vs 60/100), backed by strong 24.4% margins and 27.0% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BlackRock Inc
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
BlackRock, Inc. is an American multinational investment management corporation based in New York City.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?